Publications by authors named "N A Shackel"
Primary liver cancer is an increasing problem worldwide and is associated with significant mortality. A popular method of modeling liver cancer in mice is plasmid hydrodynamic tail vein injection (HTVI). However, plasmid-HTVI models rarely recapitulate the chronic liver injury which precedes the development of most human liver cancer.
View Article and Find Full Text PDFArticle Synopsis
- - The study explores combining the thyroid hormone receptor (THR)-β agonist resmetirom (MGL) with the mitochondrial uncoupler BAM15 to enhance treatment for metabolic dysfunction-associated steatohepatitis (MASH), since over 60% of MGL patients do not see improvement.
- - Male mice were treated with either MGL, BAM15, both, or no treatment for 8 weeks after being on a GAN diet for 38 weeks, with evaluations based on body weight, energy expenditure, and liver health.
- - The combination of MGL and BAM15 led to greater improvements in liver fat loss, energy usage, and glucose control compared to either drug alone, suggesting potential benefits of combination therapy
Background: Hepatocellular carcinoma (HCC) is the fastest increasing cause of cancer death in Australia. A recent Australian consensus guidelines recommended HCC surveillance for cirrhotic patients and non-cirrhotic chronic hepatitis B (CHB) patients at gender and age specific cut-offs. A cost-effectiveness model was then developed to assess surveillance strategies in Australia.
View Article and Find Full Text PDFAlthough there are several established international guidelines on the management of hepatocellular carcinoma (HCC), there is limited information detailing specific indicators of good quality care. The aim of this study was to develop a core set of quality indicators (QIs) to underpin the management of HCC. We undertook a modified, two-round, Delphi consensus study comprising a working group and experts involved in the management of HCC as well as consumer representatives.
View Article and Find Full Text PDF